Cefotaxime veterinary grade API intended for injectable powders is processed as a sterile sodium salt and filled as a dry powder into 10R or 20R Type I borosilicate glass vials. The fill mass is corrected for the sodium counterion: 1.048 g of cefotaxime sodium provides 1.0 g cefotaxime free acid. Sterile cefotaxime sodium is produced by aseptic crystallisation and vacuum drying because gamma irradiation and dry heat terminal sterilisation degrade the beta-lactam ring above 40 °C. Aseptic filling is executed in an ISO 14644-1 class 5 cleanroom under unidirectional airflow. The powder is passed through a 0.5 mm stainless steel sieve and dosed with a screw auger filler equipped with gravimetric checkweighing. Fill weight tolerance is controlled at ±5% for a 1 g target at line speeds below 30 vials/min. The vial is closed with 20 mm chlorobutyl rubber stoppers and aluminium flip-off seals. Container closure integrity is verified by vacuum decay per USP <1207.2>. Dry powder contains not more than 2.0% water by USP <921> Method Ic. Reconstitution with water for injection produces a clear pale yellow solution at 100 mg/mL within 2 min at 20–25 °C; the reconstituted pH is 4.5–6.5.

Release testing for sterile veterinary cefotaxime sodium includes sterility by USP <71>, bacterial endotoxins by USP <85>, particulate matter by USP <788>, residual solvents by USP <467>, and identity by HPLC with retention time matching reference standard. The endotoxin limit is calculated from the K/M formula for parenteral products. For a 1 g/vial presentation, the limit is set per dose and species-specific maximum injection rate. Cefotaxime sodium is incompatible with alkaline buffers and aminoglycosides in the same intravenous line. A 0.9% saline flush is used before and after injection when other drugs are administered through the same catheter. The solution is used within 24 h at 2–8 °C or within 6 h at 25 °C; longer storage is not supported because beta-lactam hydrolysis products can act as sensitizers.

Batch-to-batch variance in cefotaxime sodium particle size affects auger filling accuracy. Particle size d90 above 150 µm increases segregation in the hopper; d90 below 75 µm increases static adhesion to metal contact parts. The filling suite maintains relative humidity below 15% at 20 °C and dew point below -20 °C. Operators use isolators with half-suit ports when handling open powder because beta-lactam dust is sensitizing. Powder bridging in the hopper is controlled by a low-frequency vibration feeder at 40 Hz. The fill line is dedicated to cephalosporin products. Non-dedicated lines require cleaning validation with HPLC swab limit at 10 ppm total carryover. The finished product is a sterile dry powder vial for reconstitution before intramuscular or intravenous administration in non-food animals under veterinary prescription.

Why Does Cefotaxime Tablet Development Require Acid-Protection Rather Than Direct Compression?

The beta-lactam ring in cefotaxime undergoes acid-catalysed hydrolysis below pH 4.5. Direct compression tablets that disintegrate in the stomach expose the active substance to gastric fluid at pH 1.0–2.0 for 60–120 min. This exposure depresses assay below the 90.0% acceptance threshold before systemic absorption is possible. Tablet development is therefore restricted to gastro-resistant formulations intended to release the API in the distal small intestine. A cefotaxime tablet core is prepared by non-aqueous wet granulation to protect the ring from moisture. API loading is kept at 15–25 wt% because higher loadings reduce tablet hardness below 50 N and increase ejection friction on a 16-station rotary press. The granulating fluid is anhydrous ethanol containing 5% povidone K30 as binder. Granulation proceeds in a high-shear granulator with impeller speed 300 rpm and chopper speed 1500 rpm. Drying is performed in a fluid bed at inlet air temperature 40 °C until loss on drying is 1.5–2.5%. The dried granules are passed through a 0.8 mm sieve and lubricated with 0.5% magnesium stearate. Compression uses 8 mm round concave punches to a target hardness of 60–90 N and friability below 1.0% per USP <1216>. The core is coated with methacrylic acid copolymer dispersion type C to a weight gain of 7–10%. Dissolution testing follows USP <711>; a common acceptance approach requires not more than 10% release in 0.1 N hydrochloric acid for 2 h and not less than 75% release in pH 6.8 phosphate buffer within 45 min. This delayed release pattern prevents gastric degradation but requires careful control of core porosity because cracks in the coat expose the API to acid. Finished tablets are packaged in aluminium/aluminium blisters with desiccant to keep water activity below 0.6. Compounded tablet use in companion animals is subject to prescribing discretion and susceptibility testing because oral bioavailability of cefotaxime is low even with enteric protection.

Compounded Capsule Handling in Small Animal Practice Remains Low-Shear and Low-Dose

Capsule formulations are compounded for non-food companion animals when parenteral administration is not feasible and a veterinarian determines that cefotaxime is the only appropriate agent. The powder blend is produced by geometric dilution in a mortar rather than high-shear mixing. A trituration sequence of 1:1, 1:2, and 1:5 API-to-lactose monohydrate steps is used to achieve a uniform blend at strengths from 10 mg to 50 mg per Size 3 hard gelatin capsule. Lactose monohydrate is dried to a water content below 0.5% before use because residual moisture accelerates beta-lactam hydrolysis. The blend bulk density is targeted at 0.45–0.60 g/cm³ to permit reproducible dosing on a manual capsule filling apparatus. Each finished capsule meets weight variation limits under USP <905> or Ph. Eur. 2.9.40. Because cefotaxime sodium is hygroscopic, capsules are stored in amber glass containers with silica gel desiccant at 20–25 °C and used within 30 days unless a longer use period is supported by stability data. This low-shear process avoids compaction and solvent exposure, but the operational boundary is that capsule content uniformity depends on operator technique; automated encapsulation gives more consistent results. Published data for this specific veterinary capsule configuration is limited, and regulatory status varies by jurisdiction.

Dry powders for extemporaneous oral suspension are prepared by blending cefotaxime veterinary grade API with a dispersing carrier in a low-RH suite. The blend is filled into amber polyethylene terephthalate bottles fitted with 33 mm child-resistant closures. A typical extemporaneous formula uses 2.5 g cefotaxime sodium, 0.5 g xanthan gum, 10 mL glycerin, and a citric acid–sodium citrate buffer at pH 5.0 to final volume 100 mL after reconstitution. The suspending system is prepared by levigating the API with glycerin to form a paste before aqueous dilution; this sequence prevents clumping and ensures the active substance wets uniformly. The reconstituted suspension at 25 mg/mL is stored at 2–8 °C and shaken before each dose. Use after reconstitution is normally limited to 7 days because beta-lactam hydrolysis products have undefined toxicological potential in non-food species. The powder blend is not terminally sterilized; it is prepared under non-sterile but controlled conditions. Water content in the dry powder is held below 1.0% by adding a silica gel sachet to each bottle. Uniformity of dosage units is evaluated by HPLC on reconstituted suspensions sampled from the top, middle, and bottom of the bottle after shaking; the acceptance range is 90.0–110.0% of label claim for each sampling point. This dosage form is suited to small companion animals and neonatal ruminants under veterinary supervision, but oral cefotaxime is not a substitute for injectable therapy in systemic infections because absorption across the intestinal epithelium is incomplete.

When Cefotaxime Granules Are Fluid-Bed Processed for Multi-Species Oral Dosing

Granulation converts low-bulk-density cefotaxime sodium powder into free-flowing granules that reduce operator dust exposure and improve filling accuracy. The process is performed in a top-spray fluid bed granulator. A binder solution of 5% povidone K30 in ethanol–water 70:30 is sprayed at an atomising air pressure of 1.5 bar. The inlet air temperature is 55 °C, the product temperature is held at 32–35 °C, and the exhaust humidity is monitored to keep granule water content below 2.0%. The target granule size is 150–500 µm; fines below 75 µm are limited to 10% by sieving per USP <786> because these particles may settle or adhere to packaging. A granule batch for sachet filling in non-food species is prepared by pre-blending cefotaxime sodium with lactose monohydrate and microcrystalline cellulose in a diffusion mixer for 20 min at 20 rpm before granulation. API loading in the final granule is adjusted to deliver the prescribed dose per kg body weight; dose-banding into 50 mg, 100 mg, and 250 mg sachets reduces compounding errors. The finished granules are filled into single-dose aluminium foil sachets under nitrogen or dry air at residual oxygen below 3%. Stability of cefotaxime granules is highly dependent on storage temperature; packaging in aluminium foil provides a water vapour transmission rate below 0.1 g/m²/day. The terminal product is an oral granule for reconstitution or direct dosing in companion animals; it is not intended for food-producing species in jurisdictions where no MRL has been established.

Feed Premix Regulatory Status and Carryover Technical Controls

Cefotaxime is not listed in Commission Regulation (EU) No 37/2010 as having a maximum residue limit in food-producing species. In the United States, 21 CFR 530.41 restricts extralabel cephalosporin use in food-producing animals. These legal boundaries mean that a conventional feed premix for cattle, swine, or poultry is not a permissible application in those jurisdictions. Published data for this specific feed premix configuration is limited. Where a national registration exists for a non-food species or a specific indication, the API is first adsorbed onto a lactose or hydrated silica carrier in a ribbon blender at 20 rpm. Homogeneity is tested by taking 10 samples from the mixer at 1× target concentration; the coefficient of variation must be below 5.0%. Carryover is managed by a validated cleaning procedure with swab and rinse sampling; acceptance limits are derived from the no-observed-effect level and the daily feed intake of the next species. The finished premix is packed in 25 kg paper bags with a polyethylene liner and labelled with a withdrawal statement where applicable. The technical limitation is not mixer performance but the absence of residue and consumer safety data. In food-producing animals, the use of cefotaxime premix is excluded by regulatory default rather than by insufficient mixing technology.

Solutions prepared from cefotaxime veterinary grade API are compounded by dissolving the sterile sodium salt in water for injection or 0.9% sodium chloride at 20–25 °C. Reconstitution at 100 mg/mL yields a clear pale yellow solution with pH 4.5–6.5. The solution is passed through a 0.22 µm membrane filter for intravenous administration if not using a terminally sterilized product. Membrane filter integrity is confirmed by bubble point testing before and after filtration. Cefotaxime sodium solutions are incompatible with sodium bicarbonate, alkaline pH adjustments, and aminoglycosides. Mixing with calcium-containing solutions may result in physical incompatibility; visual inspection is required before infusion. The filled solution is stored at 2–8 °C for no more than 24 h unless the manufacturer has validated a longer period. Color changes from pale yellow to deep amber indicate degradation and such material is discarded. For oral solutions in non-food species, the same aqueous system is used but without the requirement for sterility; preservatives are generally omitted because beta-lactam stability is not improved by common preservatives. The terminal solution is dispensed in amber glass vials and protected from light. Continuous infusion from a burette is delivered over 30–60 min to minimize high local drug concentrations that can cause phlebitis. The final injectable solution meets particulate limits per USP <788> for small-volume injection. The clinical use of cefotaxime solutions in veterinary patients is reserved to situations where culture and susceptibility data support third-generation cephalosporin therapy.